TBXT and colorectal cancer: TFT has been evaluated in early clinical trials as a single agent (Ansfield and Ramirez, 1971), but proved to be ineffective in colorectal cancer patients, probably because of its rapid and extensive degradation by TP and subsequent elimination from the body.